NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Price, Forecast & Analysis
USA - NASDAQ:NRSN - IL0011809592 - Common Stock
NRSN Key Statistics, Chart & Performance
The current stock price of NRSN is 1.04 USD. In the past month the price decreased by -9.57%. In the past year, price decreased by -19.38%.
NRSN Latest News, Press Relases and Analysis
NRSN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.6 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
Related stock screener links
About NRSN
Company Profile
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Company Info
NEUROSENSE THERAPEUTICS LTD
11 Hamenofim St., Building B
Herzliya IL
Employees: 15
Phone: 97297996183
NEUROSENSE THERAPEUTICS LTD / NRSN FAQ
Can you describe the business of NEUROSENSE THERAPEUTICS LTD?
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Can you provide the latest stock price for NEUROSENSE THERAPEUTICS LTD?
The current stock price of NRSN is 1.04 USD. The price decreased by -3.7% in the last trading session.
Does NEUROSENSE THERAPEUTICS LTD pay dividends?
NRSN does not pay a dividend.
How is the ChartMill rating for NEUROSENSE THERAPEUTICS LTD?
NRSN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists NRSN stock?
NRSN stock is listed on the Nasdaq exchange.
What is the employee count for NRSN stock?
NEUROSENSE THERAPEUTICS LTD (NRSN) currently has 15 employees.
NRSN Technical Analysis
NRSN Financial Highlights
Over the last trailing twelve months NRSN reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 25.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1037.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NRSN Forecast & Estimates
8 analysts have analysed NRSN and the average price target is 14.28 USD. This implies a price increase of 1273.08% is expected in the next year compared to the current price of 1.04.